NCT03069989 - Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 13, 2017

Primary Completion Date

July 4, 2018

Study Completion Date

July 18, 2018

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

GSK3008348

Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.

DRUG

Placebo

Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.

DRUG

[18F]-FBA-A20FMDV2

Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.

Trial Locations (3)

SW3 6HP

GSK Investigational Site, London

WC1E 6JF

GSK Investigational Site, London

Unknown

GSK Investigational Site, London